相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Article
Infectious Diseases
Giusy Tiseo et al.
Summary: The objective of this study was to identify predictors of 30-day survival in elderly patients with COVID-19. A retrospective cohort study was conducted on elderly patients hospitalized in six European sites. A predictive score (FLAMINCOV) was developed using logistic regression and validated in a separate cohort. The FLAMINCOV score showed good discrimination in predicting survival outcomes and may be beneficial for triage and management of elderly patients with COVID-19.
CLINICAL MICROBIOLOGY AND INFECTION
(2023)
Article
Infectious Diseases
Michele Bartoletti et al.
Summary: This article introduces the establishment and working process of the ESCIMD COVID-19 guidelines task force, and outlines their recommendations for COVID-19 treatment. They provide recommendations for treatment measures, while also pointing out situations where the use of certain drugs is not recommended or should be approached with caution. The article also states that these recommendations are only applicable to adult patients, and emphasizes the backgrounds and limitations of the panel members.
CLINICAL MICROBIOLOGY AND INFECTION
(2022)
Article
Pharmacology & Pharmacy
Marco Falcone et al.
Summary: This prospective observational study evaluated the relationship between early use of remdesivir and disease progression in patients with COVID-19 pneumonia. The study found that early use of remdesivir can reduce disease progression in patients with mild to moderate COVID-19. In addition, a history of dyspnea at home was independently associated with progression to severe COVID-19.
CLINICAL THERAPEUTICS
(2022)
Article
Clinical Neurology
Uxue Lazcano et al.
Summary: This study aimed to investigate the association between previous stroke and mortality after COVID-19 infection. The results showed that previous stroke was associated with a higher mortality in individuals younger than 80 years, including both ischemic and hemorrhagic stroke but not transient ischemic attack.
Review
Medicine, General & Internal
Anjum S. Kaka et al.
Summary: This review updates the evidence on the use of Remdesivir for adult patients with COVID-19. The findings suggest that Remdesivir may not significantly reduce mortality but increases the proportion of recovered patients. It may reduce time to clinical improvement and decrease serious adverse events, but may increase any adverse events.
ANNALS OF INTERNAL MEDICINE
(2022)
Review
Infectious Diseases
Todd C. Lee et al.
Summary: Based on this meta-analysis, there is a high probability that remdesivir reduces mortality for nonventilated patients with COVID-19 requiring supplemental oxygen therapy.
CLINICAL MICROBIOLOGY AND INFECTION
(2022)
Editorial Material
Medicine, Research & Experimental
John T. Sullivan
Summary: Remdesivir was the first approved therapeutic for COVID-19 treatment, showing efficacy in hospitalized and non-hospitalized patients. Current safety data does not indicate cardiovascular issues, but further evaluation is needed to assess the association with cardiovascular adverse events.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE
(2022)
Article
Medicine, General & Internal
Jose-Manuel Ramos-Rincon et al.
Summary: This study found that the use of remdesivir may reduce mortality in unvaccinated very old patients hospitalized with COVID-19.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Pharmacology & Pharmacy
Ariyon Schreiber et al.
Summary: This study investigated the clinical characteristics and outcomes of patients who experienced bradycardia during treatment with remdesivir for COVID-19. The results suggest that bradycardia occurring during or shortly after remdesivir treatment may be associated with an increased rate of in-hospital mortality. However, the potential contribution of COVID-19 and its cardiac complications to the occurrence of bradycardia cannot be excluded.
CLINICAL DRUG INVESTIGATION
(2022)
Review
Infectious Diseases
Zelalem G. Dessie et al.
Summary: Chronic comorbidities, complications, and demographic factors such as acute kidney injury, COPD, diabetes, hypertension, CVD, cancer, increased D-dimer, male gender, older age, current smoker, and obesity are identified as clinical risk factors for fatal outcomes related to coronavirus mortality, according to large dataset from 42 studies involving 423,117 patients. The findings provide valuable insights for future research, control, and prevention of the disease.
BMC INFECTIOUS DISEASES
(2021)
Article
Medicine, General & Internal
Michael E. Ohl et al.
Summary: This study examined the association between remdesivir treatment and survival as well as length of hospital stay among COVID-19 patients. The results showed that remdesivir treatment was not associated with improved survival but was linked to longer hospital stays.
Review
Cell Biology
Ioannis P. Trougakos et al.
Summary: The article discusses the two-phase nature of COVID-19, highlighting the characteristics of increased virus transmission and uncontrolled inflammatory immune responses which can lead to severe complications. The focus is on approaches to suppress viral infection rates, activate adaptive immune responses, and mitigate tissue damage and cytokine storms associated with COVID-19.
JOURNAL OF BIOMEDICAL SCIENCE
(2021)
Review
Pharmacology & Pharmacy
Michael A. Veronin et al.
Summary: This review examines the investigational drug remdesivir and its potential as a treatment for COVID-19 through a series of questions and answers. It highlights the need for further research to clarify the selection of patients, effectiveness, and duration of treatment when using remdesivir for COVID-19.
JOURNAL OF PHARMACY TECHNOLOGY
(2021)
Article
Microbiology
Muneerah M. Aleissa et al.
Summary: Remdesivir has been approved for treating hospitalized patients with COVID-19, showing improved survival rates and decreased viral RNA levels when used early in the course of the disease.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
(2021)
Article
Geriatrics & Gerontology
Clara Bonanad et al.
JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION
(2020)
Article
Medicine, General & Internal
Yeming Wang et al.
Review
Medicine, General & Internal
Reed A. C. Siemieniuk et al.
BMJ-BRITISH MEDICAL JOURNAL
(2020)
